Objective:To investigate the effect of engeleukin combined with metoprolol therapy on prealbumin,cardiac enzymes and ventricular remodelling in patients with coronary heart disease combined with heart failure.Methods:A total of 104 patients with coronary heart disease complicated by heart failure were divided into a control group and an observation group according to different treatment methods,with 52 cases in each group.Both groups received conventional treatments including positive inotropic therapy,diu-retics,and infection control.The control group was treated with metoprolol in addition to standard treatment,while the observation group received empagliflozin in conjunction with the treatment given to the control group,with a course of treatment of 6 months.The efficacy of treatment,serological indicators[prealbumin(PA),albumin(ALB),brain natriuretic peptide(BNP),cardiac troponin I(cTnI)],myocardial enzymes[lactate dehydrogenase(LDH),creatine kinase(CK),creatine kinase-MB(CK-MB)],Cardiac function[left ventricular ejection fraction(LVEF),left ventricular end-diastolic diameter(LVEDD),left ventricular end-systolic diameter(LVESD)]before and after 6 months of treatment,and the occurrence of adverse reactions were compared between the two groups.Re-sults:The treatment effectiveness rate of the observation group was higher than that of the control group(P<0.05).After6 months of treatment,the levels of PA,ALB and LVEF in the observation group were higher than those in the control group(P<0.05),and the levels of BNP,cTnⅠ,LDH,CK,CK-MB,LVEDD and LVESD were lower than those in the control group(P<0.05).There was no sig-nificant difference in the incidence of adverse reactions between the two groups of patients compared with each other(P＞0.05).Con-clusion:In the treatment of coronary heart disease combined with heart failure,the combination of Empagliflozin treatment can improve the therapeutic effect,facilitate the improvement of ventricular remodelling and cardiac function,with better safety.